Clinical implications of serum hepatitis b virus pregenomic rna kinetics in chronic hepatitis b patients receiving antiviral treatment and those achieving hbsag loss

研究成果: Article同行評審

摘要

Serum hepatitis B virus (HBV) pregenomic RNA (pgRNA) is correlated with covalently closed circular DNA. We aimed to investigate the utility of serum HBV pgRNA in chronic hepatitis B patients receiving nucleos(t)ide analogue treatment and those achieving HBsAg loss. One hun-dred and eighty-five patients were enrolled for studying long-term HBV pgRNA kinetics during treatment. Twenty patients achieving HBsAg loss after treatment were enrolled for examining HBV pgRNA kinetics around HBsAg loss. HBV pgRNA significantly decreased in the high baseline HBV pgRNA (≥6 log copies/mL) group but significantly increased in the low baseline HBV pgRNA (<4 log copies/mL) group after 3-month entecavir treatment. Among the 20 patients achieving HBsAg loss, 13 (65%) patients had serum HBV pgRNA higher than the limit of detection (LOD, 1466 cop-ies/mL) when they achieved HBsAg loss. Finally, all 20 patients had HBV pgRNA going below the LOD within 3 years after achieving HBsAg loss. In conclusion, baseline serum HBV pgRNA alone is insufficient for predicting the trajectory of HBV pgRNA. Most patients still had HBV pgRNA higher than the LOD when they achieved HBsAg loss. Further studies on HBV pgRNA kinetics around HBsAg loss would provide an enhanced basis for further applications of HBV pgRNA.

原文English
文章編號1146
期刊Microorganisms
9
發行號6
DOIs
出版狀態Published - 2021 六月

All Science Journal Classification (ASJC) codes

  • 微生物學
  • 微生物學(醫學)
  • 病毒學

指紋

深入研究「Clinical implications of serum hepatitis b virus pregenomic rna kinetics in chronic hepatitis b patients receiving antiviral treatment and those achieving hbsag loss」主題。共同形成了獨特的指紋。

引用此